Navigation Links
Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain
Date:5/23/2013

MENLO PARK, Calif., May 23, 2013 /PRNewswire/ -- Virobay, Inc. today announced that their development of an oral treatment for pain has reached an important milestone, as Virobay has now initiated a Phase 1 clinical trial of VBY-036 - a selective cathepsin S inhibitor.  

The first Phase 1 trial of VBY-036 is a double-blind, randomized, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of VBY-036 in healthy adults.

"The initiation of this Phase 1 trial with VBY-036 represents another significant development objective for Virobay," stated Robert Booth , Ph.D., Chief Executive Officer of Virobay.  "Published preclinical data suggest that cathepsin S inhibition may provide a therapeutic benefit in patients with a variety of painful disorders, including neuropathic pain.  In addition, research carried out by Virobay with selective cathepsin S inhibitors has demonstrated efficacy in preclinical models of both acute and chronic inflammatory pain and neuropathic pain," stated Robert Booth .  "We look forward to assessing the data from these Phase 1 trials, which will incorporate the evaluation of several biomarkers, to guide our Phase 2 clinical development plans for VBY-036.  To the best of our knowledge, VBY-036 is first-in-class with this therapeutic approach for the treatment of pain."

"Reaching this important milestone brings us one step closer to providing a new treatment for patients suffering with painful conditions.  Virobay is committed to providing novel therapies for unmet medical needs and strives to constantly expand and improve treatment options for patients.  Virobay also initiated clinical studies with VBY-891, a selective cathepsin inhibitor in March of this year.  VBY-891 is being developed in partnership with LEO Pharma for the
'/>"/>

SOURCE Virobay, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
2. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
3. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
4. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
5. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
6. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
7. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
8. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
9. Applied Genetics Initiates Commercial Operation
10. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
11. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014   ISN ... & Safety Performance Indicators publication series. With ... of activity reported in 2013 within its online contractor ... and safety key performance indicator (KPI) statistics. ... Clients, U.S. publication is available in two ...
(Date:12/17/2014)... Based on the revenues gained from ... is dominated by four major players contributing to ... players include GE Healthcare (U.K.), Siemens AG (Germany), ... Full Report Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html , ... attributed to its strong product portfolio, which includes ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
(Date:12/17/2014)... Xeno Diagnostics has again received ... recent COLA inspection. Xeno has met all criteria ... accreditation organization. Accreditation is earned only by laboratories ... operations, demonstrate continued accuracy in the performance of ... survey. , While the Laboratory Excellence ...
Breaking Biology Technology:ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2
... Bio-Matrix Scientific Group Inc. (OTC Bulletin Board: BMSN)( ... Inc., its wholly owned subsidiary, announced today they have ... Army Medical Research and Materiel Command (USAMRMC) for consideration ... stem cells (ASCs) harvested from liposuction for treating Traumatic ...
... PARSIPPANY, N.J., May 4 Arno Therapeutics, Inc. (OTC ... oncology therapeutics, today announced that it has voluntarily filed ... ("SEC") in order to deregister its common stock under ... a result, effective immediately, Arno,s obligation to file periodic ...
... Develop Powerful Tools for Detecting Ovarian Cancer Earlier FRANKLIN ... (Becton, Dickinson and Company) (NYSE: BDX ) ... a worldwide development and supply agreement for oncology diagnostic ... develop diagnostic products that incorporate Fujirebio Diagnostics, cancer biomarkers ...
Cached Biology Technology:Bio-Matrix Scientific Group & Entest BioMedical Submit Research Proposal to U.S. Army for Funding Adipose-Derived Stem Cells to Treat Traumatic Brain Injury 2Arno Therapeutics to Deregister its Common Stock under the Exchange Act 2Arno Therapeutics to Deregister its Common Stock under the Exchange Act 3BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management 2BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management 3BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management 4
(Date:11/21/2014)... Nov. 20, 2014 Strict laws against distracted ... piloting the North American and European automotive sector towards ... gesture recognition systems that are intuitive and able to ... the industry. New analysis from Frost ... Market in Europe and ...
(Date:11/18/2014)... Nov. 17, 2014   News ... collaborate to develop The Partners Data Lake, an ... Partners Data Lake will allow researcher and clinicians ... treatment and the lives of patients , ... clinical activities across the Partners system, breaking down ...
(Date:11/12/2014)... 12, 2014 Crossmatch™, a leading provider of ... ® fingerprint readers have been deployed throughout Montparnasse ... Central Mexico . The bakery chain implemented the ... issues caused by employees clocking in for each other. ... readers, Montparnasse relied on paper timecards and a mechanical ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... infects more than 170 million people worldwide. Approximately 80 ... cirrhosis, cancer and also hepatic iron overload. A new ... School of Medicine reveals that HCV not only alters ... 1 (TfR1) but that TfR1 also mediates HCV entry. ...
... For more than a decade, scientists have suspected that hairpin-shaped ... scientists at NC State University have found the first example ... The research, published online in Proceedings of the ... describes how one strand of micro-RNA reduced by more than ...
... and the Woodrow Wilson International Center for Scholars are ... Foundation (NSF) to help realize potential benefits and to ... The grant is supported jointly by three units ... the Division of Environmental Biology, and the Engineering Directorate. ...
Cached Biology News:New Loyola study on hepatitis C virus entry factor 2
...
... Kit Components , 25 g Blocking Reagent , ... 10 ml T7 Elution Buffer , 0.2 ml BL21 ... 0.2 ml BLT5615 glycerol stock , 1010 pfu ... Control Lysate , 50 l S-protein HRP Conjugate , ...
Mouse monoclonal [7A6] to NFAT2 ( Abpromise for all tested applications). entrezGeneID: 4772 SwissProtID: O95644...
... Kits are designed for ultra-sensitive detection ... or PVDF membranes. Since all necessary ... primary antibodies), the WesternBreeze Kits save ... protocol and getting your final results. ...
Biology Products: